Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
NASH
Research
Organoids offer NAFLD insights and potential drug target
There's less focus on early-stage NAFLD treatments compared to NASH meds, largely because there are no reliable models. Organoids could change that.
Helen Floersh
Feb 28, 2023 12:27pm
Arrowhead’s $3.7B J&J deal is done, CEO says
Feb 15, 2023 1:12pm
J&J strikes down Arrowhead NASH pact; fate of hep B deal unknown
Feb 15, 2023 9:22am
Lilly drops program against NASH target that caught Pfizer's eye
Feb 2, 2023 8:45am
Pinnacle buys Texas research group with focus on NASH trials
Jan 11, 2023 3:15pm
Viking accuses Chinese biotech of 'ruse' to raid trade secrets
Jan 3, 2023 6:30am
